Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions

Jon Owen Ebbert, Laveena Chhatwani, Marie Christine Aubry, Jason Wampfler, Shawn Stoddard, Fang Zhang, Guibin Qiao, Mariza De Andrade, Ping Yang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Introdution: To assess clinical features of bronchioloalveolar carcinoma (BAC) based on the 1999 World Health Organization Classification ("pure BAC"), compare patients with pure BAC with patients previously diagnosed as BAC not meeting the 1999 definition, and compare survival changes of pure BAC based on the old and new (2009) staging systems. Methods:A pulmonary pathologist reviewed each BAC tumor diagnosed between January 1, 1997, and December 31, 2007, identifying cases meeting the new criteria. Cases were restaged according to the seventh edition of the tumor, node, metastasis classification introduced in 2009. Patients with pure BAC were analyzed under both staging systems for changes in overall survival estimation. Results: Of 338 total patients who were diagnosed with BAC, 117 were classified as pure and 221 were non-pure BAC. Seventy-eight of the 117 and 178 of the 221 had no other primary lung cancer. One-year and 5-year survival for the 78 patients with pure BAC were 94.8 and 83.5%, and for the 178 patients were 92.6 and 46.4%, respectively. Restaging for pure BAC cases resulted in nine of the 78 cases (12%) changing stage. Compared with the old staging, patients with advanced stage under the new stage had a worse 5-year survival (53% versus 45%), but no change was observed for stage IA. Conclusions: For patients with pure BAC, the new pathologic system favorably affects survival and the new staging system may more accurately reflect prognosis in advanced stage cancer. Our results have important implications for researchers, clinicians, and patients.

Original languageEnglish (US)
Pages (from-to)1213-1220
Number of pages8
JournalJournal of Thoracic Oncology
Volume5
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Bronchiolo-Alveolar Adenocarcinoma
Survival
Neoplasms
Lung Neoplasms

Keywords

  • Bronchioloalveolar carcinoma
  • Epidemiology
  • Lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions. / Ebbert, Jon Owen; Chhatwani, Laveena; Aubry, Marie Christine; Wampfler, Jason; Stoddard, Shawn; Zhang, Fang; Qiao, Guibin; De Andrade, Mariza; Yang, Ping.

In: Journal of Thoracic Oncology, Vol. 5, No. 8, 08.2010, p. 1213-1220.

Research output: Contribution to journalArticle

Ebbert, Jon Owen ; Chhatwani, Laveena ; Aubry, Marie Christine ; Wampfler, Jason ; Stoddard, Shawn ; Zhang, Fang ; Qiao, Guibin ; De Andrade, Mariza ; Yang, Ping. / Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions. In: Journal of Thoracic Oncology. 2010 ; Vol. 5, No. 8. pp. 1213-1220.
@article{c2fbf580c50849599f95e9a4918114e6,
title = "Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions",
abstract = "Introdution: To assess clinical features of bronchioloalveolar carcinoma (BAC) based on the 1999 World Health Organization Classification ({"}pure BAC{"}), compare patients with pure BAC with patients previously diagnosed as BAC not meeting the 1999 definition, and compare survival changes of pure BAC based on the old and new (2009) staging systems. Methods:A pulmonary pathologist reviewed each BAC tumor diagnosed between January 1, 1997, and December 31, 2007, identifying cases meeting the new criteria. Cases were restaged according to the seventh edition of the tumor, node, metastasis classification introduced in 2009. Patients with pure BAC were analyzed under both staging systems for changes in overall survival estimation. Results: Of 338 total patients who were diagnosed with BAC, 117 were classified as pure and 221 were non-pure BAC. Seventy-eight of the 117 and 178 of the 221 had no other primary lung cancer. One-year and 5-year survival for the 78 patients with pure BAC were 94.8 and 83.5{\%}, and for the 178 patients were 92.6 and 46.4{\%}, respectively. Restaging for pure BAC cases resulted in nine of the 78 cases (12{\%}) changing stage. Compared with the old staging, patients with advanced stage under the new stage had a worse 5-year survival (53{\%} versus 45{\%}), but no change was observed for stage IA. Conclusions: For patients with pure BAC, the new pathologic system favorably affects survival and the new staging system may more accurately reflect prognosis in advanced stage cancer. Our results have important implications for researchers, clinicians, and patients.",
keywords = "Bronchioloalveolar carcinoma, Epidemiology, Lung cancer",
author = "Ebbert, {Jon Owen} and Laveena Chhatwani and Aubry, {Marie Christine} and Jason Wampfler and Shawn Stoddard and Fang Zhang and Guibin Qiao and {De Andrade}, Mariza and Ping Yang",
year = "2010",
month = "8",
doi = "10.1097/JTO.0b013e3181e2f645",
language = "English (US)",
volume = "5",
pages = "1213--1220",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "8",

}

TY - JOUR

T1 - Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions

AU - Ebbert, Jon Owen

AU - Chhatwani, Laveena

AU - Aubry, Marie Christine

AU - Wampfler, Jason

AU - Stoddard, Shawn

AU - Zhang, Fang

AU - Qiao, Guibin

AU - De Andrade, Mariza

AU - Yang, Ping

PY - 2010/8

Y1 - 2010/8

N2 - Introdution: To assess clinical features of bronchioloalveolar carcinoma (BAC) based on the 1999 World Health Organization Classification ("pure BAC"), compare patients with pure BAC with patients previously diagnosed as BAC not meeting the 1999 definition, and compare survival changes of pure BAC based on the old and new (2009) staging systems. Methods:A pulmonary pathologist reviewed each BAC tumor diagnosed between January 1, 1997, and December 31, 2007, identifying cases meeting the new criteria. Cases were restaged according to the seventh edition of the tumor, node, metastasis classification introduced in 2009. Patients with pure BAC were analyzed under both staging systems for changes in overall survival estimation. Results: Of 338 total patients who were diagnosed with BAC, 117 were classified as pure and 221 were non-pure BAC. Seventy-eight of the 117 and 178 of the 221 had no other primary lung cancer. One-year and 5-year survival for the 78 patients with pure BAC were 94.8 and 83.5%, and for the 178 patients were 92.6 and 46.4%, respectively. Restaging for pure BAC cases resulted in nine of the 78 cases (12%) changing stage. Compared with the old staging, patients with advanced stage under the new stage had a worse 5-year survival (53% versus 45%), but no change was observed for stage IA. Conclusions: For patients with pure BAC, the new pathologic system favorably affects survival and the new staging system may more accurately reflect prognosis in advanced stage cancer. Our results have important implications for researchers, clinicians, and patients.

AB - Introdution: To assess clinical features of bronchioloalveolar carcinoma (BAC) based on the 1999 World Health Organization Classification ("pure BAC"), compare patients with pure BAC with patients previously diagnosed as BAC not meeting the 1999 definition, and compare survival changes of pure BAC based on the old and new (2009) staging systems. Methods:A pulmonary pathologist reviewed each BAC tumor diagnosed between January 1, 1997, and December 31, 2007, identifying cases meeting the new criteria. Cases were restaged according to the seventh edition of the tumor, node, metastasis classification introduced in 2009. Patients with pure BAC were analyzed under both staging systems for changes in overall survival estimation. Results: Of 338 total patients who were diagnosed with BAC, 117 were classified as pure and 221 were non-pure BAC. Seventy-eight of the 117 and 178 of the 221 had no other primary lung cancer. One-year and 5-year survival for the 78 patients with pure BAC were 94.8 and 83.5%, and for the 178 patients were 92.6 and 46.4%, respectively. Restaging for pure BAC cases resulted in nine of the 78 cases (12%) changing stage. Compared with the old staging, patients with advanced stage under the new stage had a worse 5-year survival (53% versus 45%), but no change was observed for stage IA. Conclusions: For patients with pure BAC, the new pathologic system favorably affects survival and the new staging system may more accurately reflect prognosis in advanced stage cancer. Our results have important implications for researchers, clinicians, and patients.

KW - Bronchioloalveolar carcinoma

KW - Epidemiology

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=77955095701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955095701&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181e2f645

DO - 10.1097/JTO.0b013e3181e2f645

M3 - Article

C2 - 20592627

AN - SCOPUS:77955095701

VL - 5

SP - 1213

EP - 1220

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 8

ER -